

DAFTAR PUSTAKA

1. Suwitra K. Penyakit ginjal kronik. Dalam Buku Ajar Ilmu Penyakit Dalam. Ed keenam Jilid II. Editor oleh Setiati S, Alwi I, Sudoyo AW, Simadibrata KM, Setiyohadi B, Syam AF. Jakarta: Interna publishing. 2014: 2159 – 65.
2. KDIGO. Clinical Practice guideline for the evaluation and management of chronic kidney disease. 2012.
3. Pusat Data dan Informasi Kementerian Kesehatan RI. Situasi Penyakit Ginjal Kronis. 2017.
4. Hill NR, Fatoba ST, Oke JL, Hirst JA, O'Callaghan CA, Lasserson DS, *et al.* Global prevalence of chronic kidney disease – a systematic review and meta-analysis. PLOS One. 2016: 1 – 18.
5. Saran R, Robinson B, Abbott KC, Bragg-Gresham J, Chen X, Gu H, *et al.* US Renal Data System 2019 Annual Data Report: Epidemiology of kidney disease in the United States. Am J Kidney Dis. 2020; 75(1): 1 – 2.
6. Medina AM, Zubero EE, Jimenez MA, Barragen SA, Garcia CA, Gutierrez JF, *et al.* NOS3 polymorphisms and chronic kidney disease. J Bras Nefrol. 2018; 40(3): 273 – 7.
7. Badan Penelitian dan Pengembangan Kesehatan. Riset Kesehatan Dasar (RISKESDAS) 2013. Lap Nas 2013. 2013: 1 – 384.
8. Aisara S, Azmi S, Yanni M. Gambaran klinis penderita penyakit ginjal kronik yang menjalani hemodialisis di RSUP dr. M. Djamil Padang. Jurnal Kesehatan Andalas. 2018; 7(1): 1 – 9.
9. Perkumpulan Nefrologi Indonesia (PERNEFRI). 10th report of Indonesian Renal Registry. 2017.
10. Diaz-Ricart M, Torramade-Moix S, Pascual G, Palomo M, Moreno-Castano A, Martinez-Sanchez J, *et al.* Endothelial damage, inflammation and immunity in chronic kidney disease. Toxins. 2020; 12(6): 1 – 21.
11. Fitzgerald J, Dalbeth N, Mikuls T, Brignardello-Peterson R, Guyatt G, Abeles A, *et al.* 2020 American college of rheumatology guideline for the management of gout. Arthritis Care Res. 2020; 72(6): 744 – 60.

12. Liu X, Liu K, Sun Q, Wang Y, Meng J, Xu Z, *et al.* Efficacy and safety febuxostat for treating hyperuricemia in patients with chronic kidney disease and in renal transplant recipients: A systematic review and meta-analysis. *Exp Ther Med.* 2018; 16: 1859 – 65.
13. Prasad Sah OS, Qing YX. Association between hyperuricemia and chronic kidney disease: a review. *NU Monthly.* 2015; 7(3): 1 – 5.
14. Sarpal V. Serum uric acid level in patients with chronic kidney disease: A prospective study. *Int J Sci Study.* 2017; 4(11): 200 – 5.
15. Tsai C, Lin S, Kuo C, Huang C. Serum uric acid and progression of kidney disease: A longitudinal analysis and mini-review. *PLOSone.* 2017: 1 – 16.
16. Uchida S, Chang W, Ota T, Tamura Y, Shiraishi T, Kumagal T, *et al.* Targeting uric acid and the inhibition of progression to end stage renal disease-A propensity score analysis. *PLOSone.* 2015; 10(12): 1 – 16.
17. Kanbay M, Yilmaz M, Sonmez A, Turgut F, Saglam M, Cakir E, *et al.* Serum uric acid level and endothelial dysfunction in patients with nondiabetic chronic kidney disease. *Am J Nephrol.* 2011; 33: 298 – 304.
18. Ochodnický P, Vettoretti S, Henning RH, Buikema H, Van Dokkum R, de Zeeuw D. Endothelial dysfunction in chronic kidney disease: determinant of susceptibility to end organ damage and therapeutic response. *J Nephrol.* 2006; 19: 246 – 258.
19. Nakayama T, Sato W, Kosugi T, Zhang L, Yoshimura A, Johnson RJ, *et al.* Endothelial injury due to eNOS deficiency accelerates of chronic renal disease in the mouse. *Am J Physiol Renal Physiol.* 2008; 296: 317 – 27
20. Darwin E, Elfi E, Elvira D. Endotel: fungsi dan disfungsi. *Andalas University Press.* 2018: 1 – 186.
21. Kurniawan A, Yanni M. Pemeriksaan fungsi endotel pada penyakit kardiovaskular. *Journal Human Care.* 2020; 5(3): 638 – 649.
22. Pisano A, Cernaro V, Gembillo G, D'Arrigo, Buemi M, Bolignano D. Xanthine oxidase inhibitors for improving renal function in chronic kidney disease patients: an updated systematic review and meta-analysis. *Int J Mol Sci.* 2017; 18: 1 – 19.

23. Chatterjee A, Catravas J. Endothelial nitric oxide (NO) and its pathophysiological regulation. *Vasc Pharmacol*. 2008; 49(4-6): 134 – 140.
24. Heiss C, Rodriguez A, Kelm M. Central role of eNOS in the maintenance of endothelial homeostasis. *Antioxid Redox Signal*. 2015; 22(14): 1 – 13.
25. Hess B. Biochemistry and biology of plasma enzymes. In: *Enzymes in blood plasma*. Academic Press. 2007: 5 – 68.
26. Heeringa P, van Goor H, Itoh-Lindstrom Y, Maeda Y, Falk RJ, Assmann KJM, *et al*. *Am J Pathol*. 2000; 156(3): 879 – 888.
27. Nakayama T, Sato W, Kosugi T, Zhang L, Yoshimura A, Johnson RJ, *et al*. Endothelial injury due to eNOS deficiency accelerates of chronic renal disease in the mouse. *Am J Physiol Renal Physiol*. 2008; 296: 317 – 27
28. Takahashi T, Harris RC. Role of endothelial nitric oxide synthase in diabetic nephropathy: Lessons from diabetic eNOS knockout mice. *J Diabetes Res*. 2014: 1 – 17
29. Sumarya M. Hiperurisemia sebagai faktor risiko penyakit kardiovaskular melalui mekanisme stres oksidatif. *Widya Biologi*. 2019; 10(02): 87 – 98.
30. Kumagai T, Ota T, Tamura Y, Chang W, Shibata S, Uchida S. Time to target uric acid to retard CKD progression. *Clin Exp Nephrol*. 2017; 21: 182 – 192.
31. Uchida S, Chang W, Ota T, Tamura Y, Shiraishi T, Kumagal T, *et al*. Targeting uric acid and the inhibition of progression to end stage renal disease-A propensity score analysis. *PLOSone*. 2015; 10(12): 1 – 16.
32. Jalal DI, Maahs DM, Hovind P, Nakagawa T. Uric acid as a mediator of diabetic nephropathy. *Semin Nephrol*. 2011; 31(5): 459 – 465.
33. Pisano A, Cernaro V, Gembillo G, D'Arrigo, Buemi M, Bolignano D. Xanthine oxidase inhibitors for improving renal function in chronic kidney disease patients: an updated systematic review and meta-analysis. *Int J Mol Sci*. 2017; 18: 1 – 19.

34. Goicoechea M, Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincon A, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. *Clin J Am Soc Nephrol*. 2010; 5: 1 – 7.
35. Weng S, Tarng D, Chen Y, Wu M. Febuxostat is superior to traditional urate-lowering agents in reducing the progression of kidney function in chronic kidney disease patients. *Cogent Medicine*. 2016; 3: 1 – 13.
36. Putri AY, Thaha M. Role of oxidative stress on chronic kidney disease progression. *Acta Med Indones*. 2014; 46(3): 244 – 52.
37. Schnaper HW. Remnant nephron physiology and the progression of chronic kidney disease. *Pediatr Nephrol*. 2014; 29(2): 1 – 17.
38. Levey A, Coresh J. Chronic Kidney disease. *Lancet*. 2012; 379(9811): 165 – 180.
39. Mihai S, Codrici E, Popescu I, Enciu A, Necula LG, Anton G, et al. Inflammation and chronic kidney disease: Current approaches and recent advances. *Chronic Kidney Disease – from Pathophysiology to Clinical Improvements*. 2018: 130 – 152.
40. Cachofeiro V, Goicoechea M, Vinuesa S, Qubina P, Lahera P, Luno J. Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. *Kidney Int*. 2008; 111: 54 – 59.
41. Ling X, Kuo K. Oxidative stress in chronic kidney disease. *Ren Replace Ther*. 2018; 4(53): 1 – 9.
42. Maiuolo J, Oppedisano F, Gratteri S, Muscoli C, Mollace V. Regulation of uric acid metabolism and excretion. *Int J Cardiol*. 2015: 1 – 8.
43. El Ridi R, Tallima H. Physiological functions and pathogenic potential of uric acid: A review. *J Adv Res*. 2017; 8: 487 – 93.
44. Dianati NA. Gout and hyperuricemia. *J Majority*. Lampung. 2015; 4(3): 82 – 9.
45. Johnson R, Bakris G, Borghi C, Chonchol M, Feldman D, Lanaspá M, et al. Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: Report of a scientific workshop organized by the National Kidney foundation. *Am J Kidney Dis*. 2018; 71(6): 851 – 865.

46. Kumar A, Aruna P, Naidu J, Kumar R, Srivastava A. Reviews of concepts and controversies of uric acid as antioxidant and pro-oxidant. *Arch Med Res J*. 2015; 24(1): 19 – 40.
47. Kushiyama A, Nakatsu Y, Matsunaga Y, Yamamotoya T, Mori K, Ueda K, *et al*. Role of uric acid metabolism-related inflammation in the pathogenesis of metabolic syndrome components such as atherosclerosis and nonalcoholic steatohepatitis. *Mediators Inflamm*. 2016: 1 – 15.
48. Hariharan C, Suresh CH. Study of serum uric acid levels in patients with chronic kidney disease and associated factors. *Int J Med Health Res*. 2017; 3(7): 80 – 83.
49. Adejumo OA, Okaka EI, Okwuonu CG, Ojogwu LI. Hyperuricemia in predialysis chronic kidney patients in Southern Nigeria. *Sahel Med J*. 2016; 19(1): 21 – 26.
50. Terawaki H, Hayashi T, Murase T, Iijima R, Waki K, Tani Y, *et al*. Relationship between xanthine oxidoreductase redox and oxidative stress among chronic kidney disease patients. *Oxid Med Cell Longev*. 2018: 1 – 6.
51. Feig DI. Hyperuricemia and hypertension. *Adv Chronic Kidney Dis*. 2012; 19(6): 377 – 85.
52. Bleakley C, Hamilton PK, Pumb R, Harbinson M, McVeigh GE. Endothelial function in hypertension: victim or culprit?. *J Clin Hypertens*. 2015; 17(8): 651 – 4.
53. Farisi S, Musfiroh I. Karakteristik senyawa inhibitor yang berpotensi selektif terhadap reseptor inducible nitrat oksida sintase (iNOS): review jurnal. *Farmaka*. 15(3): 1 – 15.
54. Han KH, Lim JM, Kim WY, Kim H, Madsen KM, Kim J. Expression of endothelial nitric oxide synthase in developing rat kidney. *Am J Physiol Renal Physiol*. 2005; 288: 694 – 702.
55. Dias RG, Negrao CE, Krieger MH. Nitric oxide and the cardiovascular system: cell activation, vascular reactivity and genetic variant. *Arq Bras Cardiol*. 2011; 96(1): 68 – 75.

56. Bellini MH, Figueira MN, Piccoli MF, Marumo JT, Cendoroglo MS, Neto MC, *et al.* Association of endothelial nitric oxide synthase gene intron 4 polymorphism with end stage renal disease. *Nephrol.* 2007; 12: 289 – 93.
57. Mount PF, Power DA. Nitric oxide in the kidney: functions and regulation of synthesis. *Acta Physiol.* 2006; 187: 433 – 46.
58. Huang P. eNOS, metabolic syndrome and cardiovascular disease. *Trends Endocrinol Metab.* 2009; 20(6): 295 – 302.
59. Govers R, Rabelink T. Cellular regulation of endothelial nitric oxide synthase. *Am J Physiol Renal Physiol.* 2001; 280: 193 – 206.
60. Shen B, Lee D, Zioncheck T. Vascular endothelial growth factor governs endothelial nitric-oxide synthase expression via a KDR/Flk-1 receptor and a protein kinase C signaling pathway. *J Biol Chem.* 1999; 274(46): 33057 – 63.
61. Sessa W. eNOs at a glance. *J Cell Sci.* 2004; 117(12): 2427 – 8.
62. Boger RH, Zoccali C. ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end stage renal disease. *Atherosclerosis Suppl.* 2003; 4: 23 – 8.
63. Hocher B, Adamski J. Metabolomics for clinical use and research in chronic kidney disease. *Nephrol.* 2017: 1 – 16.
64. Baylis C. Nitric oxide deficiency in chronic kidney disease. *Am J Physiol Renal Physiol.* 2008; 294: 1 – 9.
65. Xiao S, Schmidt RJ, Baylis C. Plasma from ESRD patients inhibits nitric oxide synthase (NOS) in cultured human and bovine endothelial cells. *Acta Phys Scand.* 2000; 168: 175 – 9.
66. Daenen K, Andries A, Mekahli D, Van Schepdael A, Jouret F, Bammens B. Oxidative stress in chronic kidney disease. *Pediatr Nephrol.* 2019; 34: 975 – 91.
67. Kajimoto H, Kai H, Aoki H, Yasuoka S, Anegawa T, Aoki Y, *et al.* Inhibition of eNOS phosphorylation mediates endothelial dysfunction in renal failure: new effect of asymmetric dimethylarginine. *Int Soc Nephrol.* 2012; 81: 762 – 8.

68. Dobrian A. ADMA and NOS regulation in chronic renal disease: beyond the old rivalry for L-arginine. *Kidney Int.* 2012; 81: 722 – 4.
69. Martens C, Edwards D. Peripheral vascular dysfunction in chronic kidney disease. *Cardiol Res Pract.* 2011; 1 – 10.
70. Zhao Y, Vanhoutte PM, Leung SWS. Vascular nitric oxide: Beyond eNOS. *J Pharmacol Sci. Hong Kong.* 2015; 129: 83 – 94.
71. Park JH, Jin YM, Hwang S, Cho DH, Kang DH, Jo I. Uric acid attenuates nitric oxide production by decreasing the interaction between endothelial nitric oxide synthase and calmodulin in human umbilical vein endothelial cells: A mechanism for uric acid induced cardiovascular disease development. *Nitric Oxide.* 2013; 32: 36 – 42.
72. Hong F, Liang X, Liu W, Lv S, He S. Roles of eNOS in atherosclerosis treatment. *Inflamm Res.* 2019; 68: 429 – 441.
73. You H, Gao T, Cooper T, Morris S, Awad S. Arginase inhibition: a new treatment for preventing progression of established diabetic nephropathy. *Am J Physiol Renal Physiol.* 2015; 309: 447 – 55.
74. Kim H, Son J, Jin E, Lee J, Park S. Effects of exercise and L-arginine intake on inflammation on aorta of high-fat diet induce obese rats. *J Exerc Nutr Biochem.* 2016; 20: 36 – 40.
75. Ryou S, Berkowitz D, Lim H. Endothelial arginase II and atherosclerosis. *Korean J Anesthesiol.* 2011; 61: 3 -11.
76. Zheng J, Lin L, Ren J, Chen A. Tetrahydrobiopterin and endothelial dysfunction. *Sheng Li Ke Xue Jin Zhan.* 2004; 35(2): 155 – 8.
77. Margaritis M, Antonopoulos A, Digby J, Lee R, Reilly S, Coutinho P, et al. Interactions between vascular wall and perivascular adipose tissue reveal novel roles for adiponectin in the regulation of endothelial nitric oxide synthase function in human vessels. *Circulation.* 2013; 127: 2209 – 21.
78. DeBecker B, Borghi C, Burnier M, van de Borne P. Uric acid and hypertension: an update. *European Society of Hypertension.* 2018; 19: 1 – 2.

79. Tousoulis D, Charakida M, Stefanadis C. Inflammation and endothelial dysfunction as therapeutic targets in patients with heart failure. *Int J Cardiol.* 2005; 100: 347 – 53.
80. Vairappan B. Endothelial dysfunction in cirrhosis: Role of inflammation and oxidative stress. *World J Hepatol.* 2015; 7(3): 443 – 59.
81. Li P, Zhang L, Zhang M, Zhou C, Lin N. Uric acid enhances PKC-dependent eNOS phosphorylation and mediates cellular ER stress: A mechanism for uric acid-induced endothelial dysfunction. *Int J Mol Med.* 2016; 37(4): 989 – 997.
82. Otero A, de Francisco A, Gayoso P, Garcia F. Prevalence of chronic renal disease in Spain: Results of EPIRCE study. *Nefrologia. Spain:* 2010. 30(1): 78 – 86.
83. Dubey A, Sahoo J, Vairappan B, Haridasan S, Parameswaran S, Priyamvada P. Correction of metabolic acidosis improves muscle mass and renal function in chronic kidney disease stages 3 and 4: a randomized controlled trial. *Nephrol Dial Transplant.* 2018: 1 – 9.
84. Doualla M, Halle M, Moutchia J, Tegang S, Ashuntantang G. Determinants of hyperuricemia in non-dialysed chronic kidney disease patients in three hospitals in Cameroon. *BMC Nephrol.* 2018; 19: 1 – 9.
85. Zeba Z, Fatema K, Sumit A, Zinnat R, Ali L. Early screening of chronic kidney disease patients among the asymptomatic adult population in Bangladesh. *J Prev Epidemiol. Bangladesh.* 2020. 5(1): 1 – 7.
86. Chang P, Chien L, Lin Y, Wu M, Chiu W, Chiou H. Risk factors of gender for renal progression in patients with early chronic kidney disease. *Medicine.* 2016. 95(30): 1 – 7.
87. Goldberg I, Krause I. The role of gender in chronic kidney disease. *Eur Med J. Israel.* 2016; 1(2): 58 – 64.
88. Baylis C. Sexual dimorphism in the aging kidney: differences in the nitric oxide system. *Nat Rev Nephrol.* 2009; 5(7): 384 – 96.

89. Roumeliotis S, Mallamaci F, Zoccali C. Endothelial dysfunction in chronic kidney disease from biology to clinical outcome: 2020 update. *J Clin Med*. 2020; 9: 1 – 27.
90. Ismail I, Mutmainnah, Hardjoeno. Nilai ureum, kreatinin, dan penyingkiran kreatinin di penderita penyakit ginjal menahun (kronik). *Indones J Clin Pathol Med Laboratory*. Surabaya. 2007; 13(3): 100 – 3.
91. Natalia D, Susilawati, Safyudin. Hubungan laju filtrasi glomerulus dengan derajat anemia pada penderita penyakit ginjal kronik. *Sriwijaya J Med*. 2019; 2(3): 177 – 189.
92. Ginawi I, Elsbali A, Ahmed H, Ashankyty I, Altamimi T, Alhasan S, et al. Population screening for chronic kidney disease and its associated risk factors: a survey in Hail region, KSA. *J Public Health Epidemiol*. 2013; 5(7): 285 – 290.
93. Ahmed H, Alzayed F, Albluwe H, Alosayfir Z, Aljarallah M, Alghazi B, et al. Etiology of chronic kidney disease (CKD) in Saudi Arabia. *Int J Med Res Health Sci*. 2019; 8(5): 177 – 182.
94. Oh T, Choi H, Kim C, Bae E, Ma S, Sung S, et al. Hyperuricemia has increased the risk of progression of chronic kidney disease: propensity score matching analysis from the KNOW-CKD study. *Sci Rep*. 2019; 9(1): 1 – 9.
95. Patil V, Patel H, Avhda A. Relation of serum uric acid level to parameters and stages of chronic kidney disease (CKD). *Pravara Med Rev*. 2020; 12(01): 23 – 29.
96. Srivastava A, Kaze A, McMullan C, Isakova T, Waikar S. Uric acid and the risks of kidney failure and death in individuals with CKD. *Am J Kidney Dis*. 2018; 71(3): 362 – 70.
97. Martinez I, Villalva R, Uribe N, Gonzalez C, Bobadilla N, Chimal J. Reduced endothelial nitric oxide synthase activation contributes to cardiovascular injury during chronic kidney disease progression. *Am J Physiol Renal Physiol*. 2019; 317: 275 – 85.

98. Aiello S, Noris M, Todeschini M, Zappella S, Foglieni C, Benigni A et al. Renal and systemic nitric oxide synthesis in rats with renal mass reduction. *Kidney Int.* 1997; 52: 171 – 81.
99. Wever R, Boer P, Hijmering M, Stroes E, Verhaar M, Kastelein J, et al. Nitric oxide production is reduced in patients with chronic renal failure. *Arterioscler Thromb Vasc Biol.* 2012; 19: 1168 – 72.
100. Annavarajula S, Dakshinamurty K, Naidu M, Reddy C. The effect of L-arginine on arterial stiffness and oxidative stress in chronic kidney disease. *Indian J Nephrol.* 1999; 22: 340 – 346.
101. Sanchez-Lozada L, Tapia E, Santamaria J, Avila-Casado C, Soto V, Nepomuceno T, et al. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. *Kidney Int.* 2005; 67(1): 237 – 47.

